Praxis Precision Medicines, Inc.

The FDA review for relutrigine is progressing with no safety or manufacturing concerns raised, and Praxis is actively preparing for a commercial launch. Multiple analysts have issued outperform and buy ratings with high price targets, reflecting strong confidence in the drug's approval trajectory and revenue potential.

The FDA granted a three-month extension to the relutrigine NDA review, pushing the PDUFA date to December 27, raising uncertainty around the timeline. The extension was triggered by the company's own submission of additional sensitivity analyses, flagged as a 'major amendment,' which introduces regulatory risk.

Truist raised its price target to $700 and maintained a Buy rating, calling the completed NDA submissions for both ulixacaltamide and relutrigine 'notable.' The dual filing demonstrates Praxis's pipeline depth and execution capability, giving investors confidence in the company's regulatory strategy.

Wedbush maintained an Underperform rating and holds persistent reservations about the ulixacaltamide filing. Wells Fargo also expressed surprise that priority review was not requested for ulixacaltamide despite its Breakthrough Therapy Designation, suggesting the company may be underutilizing regulatory advantages.

Goldman Sachs initiated coverage with a Buy rating and a $447 price target, and the analyst consensus average target of $569–$610 implies roughly 80–94% upside from current levels. Broad institutional interest, including Candriam's $20.5 million position, signals confidence in Praxis's long-term value creation.

Praxis is a clinical-stage company with a projected EPS of -$14.82 for the current year and a negative price-to-earnings ratio of -24.31, meaning it remains deeply unprofitable. The stock's high beta of 2.74 and extreme RSI readings point to speculative excess and elevated downside risk.